Minnetronix Medical Awarded National Institutes of Health Grant for Proprietary Neurapheresis Product That Removes Blood From Spinal Fluid
October 20, 2020Fast Track Small Business Innovation Research Funding Accelerates Minnetronix’s Platform Strategy to Bring Adaptable Technology and Market-Ready Products to Customers
ST. PAUL, Minn.–(BUSINESS WIRE)–#MHealth—Minnetronix Medical, which partners with companies throughout the world to design, develop and manufacture medical device technology, today announced that it has been awarded a National Institutes of Health (NIH) granti for continued study of its proprietary Neurapheresis™ Cerebrospinal Fluid Treatment Platform.ii Akin to hemodialysis, the Neurapheresis platform is designed to rapidly remove blood cells and their cytotoxic byproducts that are released into cerebrospinal fluid following an aneurysmal subarachnoid hemorrhage (SAH).
The presence of blood in the spinal fluid increases the risk of complications such as cerebral vasospasm, edema, hydrocephalus, or stroke. The Neurapheresis System enables expedited removal of blood and blood byproducts from the cerebrospinal fluid. This has been shown to shorten hospital stays, reduce use of hospital resources and improve outcomes for patients, thereby reducing the healthcare economic burden.1-3
The NIH-funded study will take place at the University of Florida Gainesville, M Health Fairview University of Minnesota Medical Center, The University of Texas Health Science Center at Houston, and New York’s Mount Sinai Hospital. This is the second in a series of clinical studies of Neurapheresis, the first having yielded positive results.
“Rapid removal of the toxins that are released into the cerebrospinal fluid when an aneurysm ruptures could be game changing and improve outcomes for patients who suffer a subarachnoid hemorrhage,” said Christopher Kellner, MD, director of the Intracerebral Hemorrhage Program at Mount Sinai and site investigator of the clinical trial at Mount Sinai. “Winning support from the NIH is another important step to completing the research necessary to evaluate the impact of this treatment strategy.”
“What fantastic validation from the medical community and the NIH that we are able to identify unmet needs and develop meaningful solutions,” said Aaron McCabe, PhD, director of research and development at Minnetronix, who is leading the Neurapheresis project. “The Minnetronix team relied on 25 years of experience to develop the platform — from concept to commercialization. Whole product solutions like this represent an expansion of our traditional offerings and create new ways for us to partner with our customers.”
The grant is the second milestone Minnetronix has announced in a month. Recently, it received FDA clearance for the MindsEye™ Port, an expandable deep brain access system used in neurosurgical procedures, that represents the launch of the company’s first technology platform. Neurapheresis is part of the company’s second platform launch.
About Minnetronix Medical
Since 1996, Minnetronix Medical has accelerated medical device breakthroughs via design, development, and manufacturing services for companies around the world. The experienced Minnetronix team works side-by-side with customers to successfully navigate increasingly complex medical device development and commercialization in the fluid and gas management, optical systems, RF/EM energy, and stimulation and active wearables markets. The company is currently developing a portfolio of solutions that advance treatment options, prevent secondary injury, and enhance healing for patients in the Neuro ICU. Minnetronix Medical is based in St. Paul, Minn. More information can be found on the Minnetronix website, by calling 651-917-4060 or emailing [email protected].
1 Panni P, Fugate JE, Rabinstein AA, Lanzino G. Lumbar drainage and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review. J Neurosurg Sci. 2017 Dec;61(6):665-672.
2 Borkar SA, Singh M, Kale SS, et al. Spinal cerebrospinal fluid drainage for prevention of vasospasm in aneurysmal subarachnoid hemorrhage: a prospective, randomized controlled study. Asian J Neurosurg. 2018;13(2):238-246.
3 Klimo P Jr, Kestle JR, MacDonald JD, Schmidt RH. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004 Feb;100(2):215-24.
i Research is supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number R44NS110247.
ii CAUTION–Investigational device. Limited by Federal (or United States) law to investigational use.
Contacts
Beth LaBreche
612-578-2834